Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00497081 · ClinicalTrials.gov registry record · Phase 2
Mirtazapine to Reduce Methamphetamine Use Among MSM With High-risk HIV Behaviors
A Phase 2 study, sponsored by San Francisco Department of Public Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT00497081 is a Phase 2 study that has completed, run by San Francisco Department of Public Health. The registered enrollment target is 60 participants.
The verdict
NCT00497081, a Phase 2 study, has completed, sponsored by San Francisco Department of Public Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
Studies demonstrate that methamphetamine (meth) use is associated with high-risk sexual behavior among MSM, putting meth-using MSM at extraordinarily high risk for transmitting or acquiring HIV. This study of intermediate size (60 participants) and length (3 months of follow-up) will assess the efficacy of mirtazapine in reducing methamphetamine use among high-risk MSM.
Interventions
- DRUG placebo
- DRUG mirtazapine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2007-05 |
| Est. Completion | 2010-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00497081
The ClinicalTrials.gov registry entry for NCT00497081 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is San Francisco Department of Public Health, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00497081 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00497081 about?
NCT00497081 is a clinical study titled "Mirtazapine to Reduce Methamphetamine Use Among MSM With High-risk HIV Behaviors". Studies demonstrate that methamphetamine (meth) use is associated with high-risk sexual behavior among MSM, putting meth-using MSM at extraordinarily high risk for transmitting or acquiring HIV. This study of intermediate size (60 participants) and length (3 months of follow-up) will assess the effi...
What is the current status of trial NCT00497081?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2007-05. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00497081?
The interventions under investigation include: placebo (DRUG), mirtazapine (DRUG).
Who is sponsoring clinical trial NCT00497081?
This trial is sponsored by San Francisco Department of Public Health, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.